APA (7th ed.) Citation

Michael Bauer, M., Andreas Weyland, M., Gernot Marx, M., Frank Bloos, M., Stephan Weber, D. S., Norbert Weiler, M., . . . Group, f. t. S. (2021). Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Wolters Kluwer.

Chicago Style (17th ed.) Citation

Michael Bauer, MD, et al. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Wolters Kluwer, 2021.

MLA (8th ed.) Citation

Michael Bauer, MD, et al. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Wolters Kluwer, 2021.